The Edge

News and insights that give you an advantage.

January 2020

Smart investments promote client and member satisfaction.

During 2019, Kirk Curtis and Cornell Beck helped take CastiaRx service and operations to a new – and extreme – level. Kirk, AVP, Contact Center, and Cornell, VP, Pharmacy Operations, partnered with key areas such as Mail Order to understand which intersecting points needed a new approach. In conjunction with a professional trainer and various internal experts, their efforts pushed service beyond previous expectations.

Read more

Account team: Growing together to serve you better.

Recent expansions on the CastiaRx Clinical and Account teams represent a commitment to strategic, clinical solutions that greatly enhance pharmacy benefit programs, the member experience and savings opportunities. “We reach across CastiaRx to collaborate with various teams to support new business, develop new clinical programs and build plans that work well for clients,” says Valerie Woerndle, Director of Clinical Operations.

Read more

A high-touch approach to plan savings.

When a large, national employer decided to address their previous PBM’s shortcomings in responsiveness, partnership and innovation, CastiaRx provided the solutions they needed. With 4,000 plan members across the US, better ways were needed to manage pharmacy costs while helping members adjust to changes in their normal process.

Read more

CastiaRx Connect: When only a text will do.

With a January 2020 launch, CastiaRx Connect promises to be a popular new tool for plan members. Recognizing that text messaging is a preferred method of communication, members receive texts that link to a secure, HIPAA-compliant web page. There, they access their own, personalized information regarding medications, refills, savings opportunities and more.

Read more

Clinical Corner: Your resource for pharmacy news.

Looking for clinical news? Clinical Corner is your go-to destination for details on safety recalls, new drug announcements, cost insights and more.

Read more

In case you missed our latest news.

Last month, we announced that we entered into an agreement to combine with OptumRx. The deal is expected to close early 2020, subject to the satisfaction of certain closing conditions. This deal allows us to deepen our capabilities to better serve the needs of you and your members. For more information, please read the press release announcing the transaction.

Important Additional Information
This communication does not constitute an offer to buy or the solicitation of an offer to sell any securities. UnitedHealth Group Incorporated and Denali Merger Sub, Inc. have filed a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission (the “SEC”) and have mailed an offer to purchase, letter of transmittal and related materials to the  shareholders of Diplomat Pharmacy, Inc. (the “Company”). The Company has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC which has also been mailed to the Company’s shareholders. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. These materials are available free of charge to Company shareholders, and may also be obtained by contacting the Company’s Investor Relations Department at 4100 S. Saginaw Street, Flint, Michigan 48507, (888) 720-4450 or tpowers@Diplomat.is or by contacting D.F. King & Co., Inc., the information agent for the tender offer, at (212) 269-5550 for banks and brokers or (866) 829-0135 for all others, or by email at DPLO@dfking.com. In addition, all of these materials (and all other tender offer documents filed with the SEC) are available at no charge from the SEC through its website at www.sec.gov.

Cautionary Statement Regarding Forward-Looking Statements
Forward-looking statements made herein with respect to the tender offer and related transactions, including, for example, the timing of the completion of the tender offer and the merger or the potential benefits of the tender offer and the merger, reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, the Company’s actual results may differ materially from its expectations or projections.

The following factors, among others, could cause actual plans and results to differ materially from those described in forward-looking statements. Such factors include, but are not limited to, the effect of the announcement of the tender offer and related transactions on the Company’s business relationships, operating results and business generally; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, and the risk that the merger agreement may be terminated in circumstances that require the Company to pay a termination fee; the outcome of any legal proceedings that may be instituted against the Company related to the transactions contemplated by the merger agreement, including the tender offer and the merger; uncertainties as to the number of shareholders of the Company who may tender their stock in the tender offer; the failure to satisfy other conditions to consummation of the tender offer or the merger, including the receipt of regulatory approvals related to the merger (and any conditions, limitations or restrictions placed on these approvals); risks that the tender offer and related transactions disrupt current plans and operations and the potential difficulties in employee retention as a result of the proposed transactions; the effects of local and national economic, credit and capital market conditions on the economy in general, and other risks and uncertainties; and those risks and uncertainties discussed from time to time in the Company’s other reports and other public filings with the SEC.

Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its periodic filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2018. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov, on the Company’s website http://ir.diplomat.is/investors/default.aspx or upon request via email to tpowers@Diplomat.is. The Company disclaims any obligation or undertaking to update or revise the forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

Thanks for reading The Edge.

We hope you find valuable information in each issue of our CastiaRx bulletin, The Edge. This bimonthly publication highlights our commitment to your success and is produced exclusively for CastiaRx clients. Please contact your account manager for more information about any topic.